I-Tyza Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. It is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. I-Tyza Capsule is administered orally and exhibits good bioavailability when taken with food, enhancing absorption. The drug is metabolized primarily by the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Rare but serious side effects may involve hepatotoxicity and congestive heart failure. I-Tyza should be used under medical supervision with appropriate monitoring of liver function and cardiac status. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals. Due to its interaction potential, a thorough review of concomitant medications is essential before initiating therapy to prevent adverse drug interactions.